Expanded Access
Expanded Access (EA) or “compassionate use” is an FDA-regulated pathway allowing a patient to receive an investigational drug outside of a clinical...
Read More2021 Update on Metastatic Triple Negative Breast Cancer Treatment
Triple-negative breast cancer (TNBC) is a breast cancer subtype that tests negative for estrogen receptors (ER), progesterone receptors (PR), and human...
Read MoreScreening for Breast Cancer Brain Metastases
Breast cancer brain metastases (BCBM) screening is when an imaging test, such as an MRI, is used to look for BCBM in a person who is not experiencing symptoms of...
Read MoreParticipating in a Trial: Patient Voices
There are many ways that medical professionals educate patients and the public about breast cancer clinical trials. One of the most effective ways of increasing...
Read MoreFDA Approves MARGENZA
On December 16, 2020, the FDA approved margetuximab-cmkb (MARGENZA®, MacroGenics) in combination with chemotherapy, for the treatment of patients with metastatic...
Read MoreTreating Breast Cancer Brain Mets
Treatment options for breast cancer brain metastases (BCBM) have historically included only surgery, radiation, and limited clinical trial access. However, due to...
Read MoreCirculating Tumor Cell Testing
A circulating tumor cell (CTC) test is a blood test that looks for tumor cells that were shed from a tumor and are now moving (circulating) through the...
Read MoreWhat You Need to Know About Washout Periods
In clinical trials, a washout period describes the length of time that someone enrolled in a trial must not receive any treatment before receiving the trial’s...
Read MoreSpotlight on MBC Podcasts
Listening to podcasts can help you feel connected to your communities, especially during the social isolation of the current pandemic. This month we highlight two...
Read MoreSEARCH OUR SITE
for past articles or specific information.